{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:08:49Z","timestamp":1788952129677,"version":"build-2803163510"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Sperm Autoantigenic Protein 17 (SPA17), a member of the cancer-testis antigen family, is frequently overexpressed in various malignancies, yet its biological functions, regulatory mechanisms, and clinical relevance in melanoma remain largely unexplored. This study aimed to investigate the expression pattern, prognostic value, and functional role of SPA17 in melanoma progression and immune modulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analyzed SPA17 expression in melanoma clinical specimens and correlated it with patient prognosis, metastatic burden, and immunotherapy response. Functional assays, including migration and proliferation tests, were performed in SPA17-knockdown melanoma cells\n                      <jats:italic>in vitro<\/jats:italic>\n                      , and tumor growth was evaluated in a subcutaneous syngeneic mouse model\n                      <jats:italic>in vivo<\/jats:italic>\n                      . Mechanistic studies involved co-culture systems with activated human lymphocytes and molecular interrogation of downstream effectors, with particular focus on AXL. The\u00a0therapeutic potential of a SPA17-targeting peptide vaccine was also assessed\u00a0in vivo, with tumor-infiltrating lymphocyte populations characterized by immunohistochemistry.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      SPA17 was markedly upregulated in melanoma tissues, especially in metastatic lesions, and high expression correlated with poor prognosis, increased metastatic burden, and resistance to immunotherapy. Knockdown of SPA17 significantly suppressed melanoma cell migration in vitro\u00a0and tumor growth\n                      <jats:italic>in vivo<\/jats:italic>\n                      , with no effect on proliferation. Mechanistically, SPA17 depletion enhanced intratumoral infiltration and cytotoxic activity of CD8\n                      <jats:sup>+<\/jats:sup>\n                      \u00a0T cells, and SPA17-knockdown melanoma cells showed reduced resistance to activated lymphocyte-mediated killing in co-culture. We identified AXL as a critical downstream effector, as SPA17 positively regulated AXL expression, and ectopic AXL overexpression rescued the migration defect and restored lymphocyte-mediated killing impaired by SPA17 knockdown. Therapeutically, administration of the SPA17-targeting peptide vaccine markedly restrained melanoma progression in vivo, accompanied by increased tumor-infiltrating CD8\n                      <jats:sup>+<\/jats:sup>\n                      \u00a0and GZMB\n                      <jats:sup>+<\/jats:sup>\n                      \u00a0CD8\n                      <jats:sup>+<\/jats:sup>\n                      \u00a0T cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Collectively, our findings suggest that SPA17 promotes melanoma progression and immune evasion through upregulation of AXL, and that SPA17-directed peptide vaccination elicits antitumor immune responses and inhibits tumor growth. These data support SPA17 as a candidate prognostic biomarker and a potential therapeutic target warranting further clinical investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1914680","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:12:03Z","timestamp":1788948723000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The SPA17-AXL axis drives melanoma aggressiveness and SPA17-targeting vaccination exhibits\u00a0antitumor efficacy"],"prefix":"10.3389","volume":"17","author":[{"given":"Lan","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]},{"name":"Department of Laboratory Medicine, Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengshu","family":"You","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]},{"name":"Department of Laboratory Medicine, Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]},{"name":"Department of Dermatology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, School of Life Sciences, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xiangya Third Hospital, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuozhong","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology Head and Neck Surgery, The Second Xiangya Hospital of Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, School of Life Sciences, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007146","article-title":"Inhibition of Tca cycle improves the anti-Pd-1 immunotherapy efficacy in melanoma cells via Atf3-mediated Pd-L1 expression and glycolysis","volume":"11","author":"Liu","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0818-3","article-title":"Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy","volume":"26","author":"Perez-Guijarro","year":"2020","journal-title":"Nat Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009662","article-title":"Toripalimab in combination with Hbm4003, an anti-Ctla-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: An open-label phase I trial","volume":"12","author":"Tang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115674","article-title":"Improved clinical outcomes with low-dose anti-Ctla-4 (Nurulimab) plus anti-Pd-1 (Prolgolimab) vs. anti-Pd-1 monotherapy in advanced cutaneous melanoma: Results from the phase Iii Octava trial","volume":"227","author":"Demidov","year":"2025","journal-title":"Eur J Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00097-8","article-title":"Ipilimumab alone or ipilimumab plus anti-Pd-1 therapy in patients with metastatic melanoma resistant to anti-Pd-(L)1 monotherapy: A multicentre, retrospective, cohort study","volume":"22","author":"Pires da Silva","year":"2021","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41419-023-05961-3","article-title":"Tigit, a novel immune checkpoint therapy for melanoma","volume":"14","author":"Tang","year":"2023","journal-title":"Cell Death Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s00262-023-03581-6","article-title":"Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma","volume":"73","author":"Versluis","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s42003-024-05845-y","article-title":"Molecular mechanism of specific Hla-a Mrna recognition by the Rna-binding-protein Hmex3b to promote tumor immune escape","volume":"7","author":"Yang","year":"2024","journal-title":"Commun Biol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70403","article-title":"Decoding Mhc loss: Molecular mechanisms and implications for immune resistance in cancer","volume":"15","author":"Lin","year":"2025","journal-title":"Clin Transl Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the Il-23 and Il-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines3040875","article-title":"A nanoparticle based Sp17 peptide vaccine exposes new immuno-dominant and species cross-reactive B cell epitopes","volume":"3","author":"Xiang","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01303.x","article-title":"Cancer\/Testis (Ct) antigens: Potential targets for immunotherapy","volume":"100","author":"Caballero","year":"2009","journal-title":"Cancer Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/science.1840703","article-title":"A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma","volume":"254","author":"van der Bruggen","year":"1991","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3390\/cells12060926","article-title":"Biology of cancer-testis antigens and their therapeutic implications in cancer","volume":"12","author":"Nin","year":"2023","journal-title":"Cells"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-0770","article-title":"Selective expression and immunogenicity of the cancer\/testis antigens Sp17, Akap4 and Pttg1 in non-small cell lung cancer: New candidates for active immunotherapy","author":"Chiriva-Internati","year":"2014","journal-title":"Chest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkn673","article-title":"Ctdatabase: A knowledge-base of high-throughput and curated data on cancer-testis antigens","volume":"37","author":"Almeida","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1669","article-title":"Cancer\/Testis antigens, gametogenesis and cancer","volume":"5","author":"Simpson","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107889","article-title":"A novel era of cancer\/testis antigen in cancer immunotherapy","volume":"98","author":"Meng","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.7111","article-title":"Selection of immunostimulant As15 for active immunization with Mage-A3 protein: Results of a randomized phase Ii study of the European Organisation for Research and Treatment of Cancer Melanoma Group in metastatic melanoma","volume":"31","author":"Kruit","year":"2013","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3390\/ijms17091525","article-title":"In vitro assessment of the expression and T cell immunogenicity of the tumor-associated antigens Boris, Muc1, Htert, Mage-A3 and Sp17 in uterine cancer","volume":"17","author":"Vanderstraeten","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30254-7","article-title":"Mage-A3 immunotherapeutic as adjuvant therapy for patients with resected, Mage-A3-positive, stage Iii melanoma (Derma): A double-blind, randomised, placebo-controlled, phase 3 trial","volume":"19","author":"Dreno","year":"2018","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltae008","article-title":"High-affinity T cell receptor Immtac(R) bispecific efficiently redirects T cells to kill tumor cells expressing the cancer-testis antigen Prame","volume":"4","author":"Ribeiro","year":"2024","journal-title":"Immunother Adv"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154546","article-title":"Sperm protein antigen 17 and sperm flagellar 1 cancer testis antigens are expressed in a rare case of ciliated foregut cyst of the common hepatic duct","volume":"247","author":"Grizzi","year":"2023","journal-title":"Pathol Res Pract"},{"key":"B24","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3390\/cancers10080276","article-title":"Sperm protein 17 expression by murine epithelial ovarian cancer cells and its impact on tumor progression","volume":"10","author":"Gao","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-011-0137-0","article-title":"Anti-Sp17 monoclonal antibody with antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities against human ovarian cancer cells","volume":"29","author":"Song","year":"2012","journal-title":"Med Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010471","article-title":"Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer","volume":"5","author":"Chiriva-Internati","year":"2010","journal-title":"PloS One"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1182\/blood.v97.5.1508","article-title":"Sperm Protein 17 Is a Novel Cancer-Testis Antigen in Multiple Myeloma","volume":"97","author":"Lim","year":"2001","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.07.094","article-title":"Mapping T and B cell epitopes in sperm protein 17 to support the development of an ovarian cancer vaccine","volume":"33","author":"Xiang","year":"2015","journal-title":"Vaccine"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10506","article-title":"Tumor vaccine for ovarian carcinoma targeting sperm protein 17","volume":"94","author":"Chiriva-Internati","year":"2002","journal-title":"Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0408","article-title":"Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma","volume":"100","author":"Chiriva-Internati","year":"2002","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6527306","article-title":"Sp17 protein expression and major histocompatibility class I and Ii epitope presentation in diffuse large B cell lymphoma patients","volume":"2017","author":"Ait-Tahar","year":"2017","journal-title":"Adv Hematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.844736","article-title":"Sperm autoantigenic protein 17 predicts the prognosis and the immunotherapy response of cancers: A pan-cancer analysis","volume":"13","author":"Tu","year":"2022","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2174\/0929867323666160405112954","article-title":"Role of the receptor tyrosine kinase Axl and its targeting in cancer cells","volume":"23","author":"Corno","year":"2016","journal-title":"Curr Med Chem"},{"key":"B34","doi-asserted-by":"publisher","first-page":"8419","DOI":"10.3390\/ijms21228419","article-title":"Axl receptor in breast cancer: Molecular involvement and therapeutic limitations","volume":"21","author":"Falcone","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-1973","article-title":"Small-molecule inhibition of Axl targets tumor immune suppression and enhances chemotherapy in pancreatic cancer","volume":"78","author":"Ludwig","year":"2018","journal-title":"Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2330","article-title":"Activation of the Axl kinase causes resistance to Egfr-targeted therapy in lung cancer","volume":"44","author":"Zhang","year":"2012","journal-title":"Nat Genet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17026","article-title":"Targeting Axl overcomes resistance to docetaxel therapy in advanced prostate cancer","volume":"8","author":"Lin","year":"2017","journal-title":"Oncotarget"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0294","article-title":"Axl mediates resistance to cetuximab therapy","volume":"74","author":"Brand","year":"2014","journal-title":"Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.1038\/s41598-022-09078-z","article-title":"Axl inhibition improves Braf-targeted treatment in melanoma","volume":"12","author":"Nyakas","year":"2022","journal-title":"Sci Rep"},{"key":"B40","doi-asserted-by":"publisher","first-page":"19997","DOI":"10.18632\/oncotarget.7671","article-title":"Fibroblast-induced switching to the mesenchymal-like phenotype and Pi3k\/Mtor signaling protects melanoma cells from Braf inhibitors","volume":"7","author":"Seip","year":"2016","journal-title":"Oncotarget"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.16.1.135","article-title":"Differential activation of the Ras\/Extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase","volume":"16","author":"Fridell","year":"1996","journal-title":"Mol Cell Biol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/iub.1285","article-title":"Axl mediates tumor invasion and chemosensitivity through Pi3k\/Akt signaling pathway and is transcriptionally regulated by Slug in breast carcinoma","volume":"66","author":"Li","year":"2014","journal-title":"IUBMB Life"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M107488200","article-title":"Gas6 induces mesangial cell proliferation via latent transcription factor Stat3","volume":"276","author":"Yanagita","year":"2001","journal-title":"J Biol Chem"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1101\/gad.351985.124","article-title":"Fatty acid uptake activates an Axl-Cav1-beta-catenin axis to drive melanoma progression","volume":"39","author":"Chocarro-Calvo","year":"2025","journal-title":"Genes Dev"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-025-03632-5","article-title":"Fra1 drives melanoma metastasis through an actionable transcriptional network","volume":"44","author":"Xu","year":"2025","journal-title":"Oncogene"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bty560","article-title":"Fastp: An ultra-fast all-in-one Fastq preprocessor","volume":"34","author":"Chen","year":"2018","journal-title":"Bioinformatics"},{"key":"B47","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"Star: Ultrafast universal Rna-Seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btt656","article-title":"Featurecounts: An efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for Rna-Seq data with Deseq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2021.100141","article-title":"Clusterprofiler 4.0: A universal enrichment tool for interpreting omics data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation (Camb)"},{"key":"B51","doi-asserted-by":"publisher","first-page":"180015","DOI":"10.1038\/sdata.2018.15","article-title":"Immport, toward repurposing of open access immunological assay data for translational and clinical research","volume":"5","author":"Bhattacharya","year":"2018","journal-title":"Sci Data"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btab561","article-title":"Ucscxenashiny: An R\/Cran package for interactive analysis of ucsc xena data","volume":"38","author":"Wang","year":"2022","journal-title":"Bioinformatics"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s42003-024-06891-2","article-title":"Facilitating integrative and personalized oncology omics analysis with ucscxenashiny","volume":"7","author":"Li","year":"2024","journal-title":"Commun Biol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13817","article-title":"Treatment of early-onset specified and unspecified bipolar disorders: A systematic review and strategies for identifying and managing a thermally dysregulated subtype in children","volume":"152","author":"Papolos","year":"2025","journal-title":"Acta Psychiatr Scand"},{"key":"B55","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s40537-023-00844-y","article-title":"Best: A web application for comprehensive biomarker exploration on large-scale data in solid tumors","volume":"10","author":"Liu","year":"2022","journal-title":"J Big Data"},{"key":"B56","doi-asserted-by":"publisher","first-page":"bbac261","DOI":"10.1093\/bib\/bbac261","article-title":"Hiplot: A comprehensive and easy-to-use web service for boosting publication-ready biomedical data visualization","volume":"23","author":"Li","year":"2022","journal-title":"Brief Bioinform"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1688","article-title":"Pd-L1 expression and immune escape in melanoma resistance to mapk inhibitors","volume":"23","author":"Kakavand","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010770","article-title":"Integrative genome comparison of primary and metastatic melanomas","volume":"5","author":"Kabbarah","year":"2010","journal-title":"PloS One"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2509","article-title":"Gene expression profiling-based identification of molecular subtypes in stage iv melanomas with different clinical outcome","volume":"16","author":"Jonsson","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/s41467-017-01460-0","article-title":"Mutational and putative neoantigen load predict clinical benefit of adoptive t cell therapy in melanoma","volume":"8","author":"Lauss","year":"2017","journal-title":"Nat Commun"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-3556","article-title":"Immune-related gene expression profiling after pd-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma","volume":"77","author":"Prat","year":"2017","journal-title":"Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct immune cell populations define response to anti-pd-1 monotherapy and anti-pd-1\/anti-ctla-4 combined therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"key":"B63","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-pd-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.gpb.2022.08.004","article-title":"Tiger: A web portal of tumor immunotherapy gene expression resource","volume":"21","author":"Chen","year":"2023","journal-title":"Genomics Proteomics Bioinf"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22463","article-title":"Clinical significance of sperm protein 17 expression and immunogenicity in esophageal cancer","volume":"120","author":"Gupta","year":"2007","journal-title":"Int J Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-429","article-title":"Sperm protein 17 is highly expressed in endometrial and cervical cancers","volume":"10","author":"Li","year":"2010","journal-title":"BMC Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1039\/c4cs00370e","article-title":"Cancer biomarker detection: Recent achievements and challenges","volume":"44","author":"Wu","year":"2015","journal-title":"Chem Soc Rev"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/nature06913","article-title":"The cancer biomarker problem","volume":"452","author":"Sawyers","year":"2008","journal-title":"Nature"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1111\/cup.13528","article-title":"Cancer-testis antigens as biomarkers for merkel cell carcinoma: Pitfalls and opportunities","volume":"46","author":"Dasgeb","year":"2019","journal-title":"J Cutan Pathol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6411","article-title":"Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy","volume":"12","author":"Sahni","year":"2023","journal-title":"Cancer Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1007\/s12672-025-03355-9","article-title":"Development and validation of g2m signature-based prognostic model for stratifying colon cancer prognosis","volume":"16","author":"Song","year":"2025","journal-title":"Discov Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/and.13986","article-title":"Identification of new biomarkers in immune microenvironment of testicular germ cell tumour","volume":"53","author":"Song","year":"2021","journal-title":"Andrologia"},{"key":"B73","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1186\/s12885-018-4880-x","article-title":"Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: A retrospective study","volume":"18","author":"Brunette","year":"2018","journal-title":"BMC Cancer"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2022.123376","article-title":"Fabrication of alkoxysilane substituted polymer-modified disposable biosensing platform: Towards sperm protein 17 sensing as a new cancer biomarker","volume":"243","author":"Yadav","year":"2022","journal-title":"Talanta"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.124325","article-title":"Biocompatible epoxysilane substituted polymer-based nano biosensing platform for label-free detection of cancer biomarker sp17 in patient serum samples","volume":"239","author":"Yadav","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1039\/d5tb00741k","article-title":"Electrochemical biosensing of sperm protein 17 in clinical samples using a hydrothermally synthesized mos(2)@rgo@mwcnts ternary system without prior pre-treatment","volume":"13","author":"Yadav","year":"2025","journal-title":"J Mater Chem B"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00710","article-title":"Sperm protein antigen 17 expression correlates with lymph node metastasis and worse overall survival in patients with breast cancer","volume":"9","author":"Zhou","year":"2019","journal-title":"Front Oncol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41392-024-02121-7","article-title":"Axl signaling in cancer: From molecular insights to targeted therapies","volume":"10","author":"Yadav","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B79","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13046-023-02726-w","article-title":"Axl in cancer: A modulator of drug resistance and therapeutic target","volume":"42","author":"Tang","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.36401\/JIPO-24-37","article-title":"Axl inhibitors in oncology clinical trials: A review","volume":"9","author":"Quach","year":"2026","journal-title":"J Immunother Precis Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.89","article-title":"The receptor tyrosine kinase axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target","volume":"32","author":"Paccez","year":"2013","journal-title":"Oncogene"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.650963","article-title":"Axl overexpression in tumor-derived endothelial cells promotes vessel metastasis in patients with hepatocellular carcinoma","volume":"11","author":"Chai","year":"2021","journal-title":"Front Oncol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1186\/s12885-022-09511-6","article-title":"Axl regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer","volume":"22","author":"Iida","year":"2022","journal-title":"BMC Cancer"},{"key":"B84","doi-asserted-by":"publisher","first-page":"5865","DOI":"10.1038\/s41467-020-19575-2","article-title":"St3gal1 is a target of the sox2-gli1 transcriptional complex and promotes melanoma metastasis through axl","volume":"11","author":"Pietrobono","year":"2020","journal-title":"Nat Commun"},{"key":"B85","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.bbrc.2023.09.021","article-title":"Axl receptor tyrosine kinase inhibition improves the anti-tumor effects of cd8(+) t cells by inducing cd103(+) dendritic cell-mediated t cell priming","volume":"680","author":"Im","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20102","article-title":"Cancer testis antigen sperm protein 17 as a new target for triple negative breast cancer immunotherapy","volume":"8","author":"Mirandola","year":"2017","journal-title":"Oncotarget"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.09.005","article-title":"Cd8(+) t cells in the cancer-immunity cycle","volume":"56","author":"Giles","year":"2023","journal-title":"Immunity"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1914680\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:12:04Z","timestamp":1788948724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1914680\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":87,"alternative-id":["10.3389\/fimmu.2026.1914680"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1914680","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1914680"}}